MusclePharm (OTC QB: MSLP) is once again in the spotlight at Forbes. For the third time in recent months, the nutritional supplement company was profiled by the business newsmagazine. The latest article, titled "Nutritional Supplements Flexing Muscles As Growth Industry," includes a discussion of MSLP's business highlights by industry expert Brian Smith.
MSLP caught the attention of Forbes earlier this year, in the article "Billionaire Pharmaceutical Entrepreneur Makes Bet On Fast Growing Supplement Manufacturer." That billionaire is Dr. Phillip Frost, who led a $12 million round of financing for MSLP in February (as discussed in another Forbes article). You can see a brief list of Dr. Frost's previous wins here.
Described by Forbes as "one of the rising stars" in the $32 billion nutritional supplement space, MSLP has achieved triple-digit annual revenue growth over the past four years, generating an estimated $78 million in 2012. The Company expects to reach $100 million in sales this year, bolstered by the strengthening international demand for its award-winning supplements. In 2012, international sales accounted for approximately 35% of total sales, up from 19% in 2011.
MSLP's products are sold in more than 10,000 U.S. retail outlets and over 110 countries, and they consistently rank among Bodybuilding.com's top 50 best sellers. The Company's devoted customer base includes professional athletes such as Ultimate Fighting champion Benson "Smooth" Henderson, San Francisco 49ers quarterback Colin Kaepernick, Denver Broncos star wide receiver Eric Decker, and international rugby superstar Quade Cooper, all of whom recently signed endorsement deals with the Company. MSLP is also the official nutritional supplement sponsor of the Ultimate Fighting Championship, the world's largest mixed martial arts organization.
One of the key drivers behind MSLP's success is its powerful scientific team. The Company's chief medical officer is a leading sports nutrition doctor, and MSLP's team includes top former researchers from GlaxoSmithKline, Bristol-Myers Squibb, Pfizer, the National Institutes of Health, and the FDA, as well as the former U.S. Assistant Surgeon General. All MSLP products are free of banned substances, and new products undergo rigorous testing at the Company's Sports Science Center in Colorado.
The recent addition of former Office Depot executive Richard Estalella to MSLP's management team should further strengthen the Company's operations. Mr. Estalella helped grow Office Depot into a $9 billion company, and his track record of delivering strong cost savings and profit improvement will be an asset to MSLP as the Company continues its rapid growth trajectory.
In recent months, shares of MSLP have appreciated from the mid-$5 range to a 52-week high of $11.89. Currently trading around $9, MSLP is poised to deliver huge gains for investors who build a position today.
Disclosure: The subject security is a client of RedChip Companies, Inc. RedChip Companies, Inc., employees and affiliates may have positions and affect transactions in the securities or options of the issuers mentioned herein. For full financial disclosures for all RedChip clients, please visit http://www.redchip.com/disclosures.asp?src=rcv.